Long-term allograft and patient outcomes of kidney transplant recipients with and without incident cancer – a population cohort study

The excess risk for cancer in kidney transplant recipients is substantial, but the allograft and patient survivals after cancer development are under-studied. This is a population-based cohort study of all primary live and deceased donor kidney transplant recipients in Australia and New Zealand between 1990-2012. The risks of overall graft loss and death with a functioning graft in kidney transplant recipients with and without incident cancer were determined using adjusted Cox regression analysis, with incident cancer considered as a time-varying covariate in the models. In those with incident cancer, types and cancer stage at diagnoses were reported. Of 12,545 transplant recipients followed for a median of 6.9 years (91,380 patient-years), 1184 (9.4%) developed incident cancers at a median of 5.8 years post-transplant. Digestive, kidney and urinary tract cancers were the most common cancer types, although digestive and respiratory tract cancers were more aggressive, with 40% reported as advanced cancers at time of cancer diagnosis. Cancer-related deaths accounted for approximately 80% of recipients with a prior cancer history. Compared with recipients with no prior cancer, the adjusted hazard ratios (HR) for overall graft loss and death with functioning graft were 4.34 (95%CI 3.90, 4.82; p<0.001) and 9.53 (95%CI 8.30, 10.95; <0.001) among those with a prior cancer. Incident cancer after kidney transplantation is a significant risk factor for death with a functioning graft, with the majority of deaths attributed to cancer. A greater understanding of the barriers to screening and treatment approaches following cancer diagnosis may lead to improve survival in kidney transplant recipients with cancer.

[1]  R. Pfeiffer,et al.  Variation in Cancer Incidence among Patients with ESRD during Kidney Function and Nonfunction Intervals. , 2016, Journal of the American Society of Nephrology : JASN.

[2]  S. Chadban,et al.  Cancer in ESRD: Clear on the Epidemiology, Hazy on the Mechanisms. , 2016, Journal of the American Society of Nephrology : JASN.

[3]  A. Sharif,et al.  Malignancy-related mortality following kidney transplantation is common. , 2014, Kidney international.

[4]  J. Craig,et al.  Death from cancer: a sobering truth for patients with kidney transplants. , 2014, Kidney international.

[5]  A. Webster,et al.  Cancer in the transplant recipient. , 2013, Cold Spring Harbor perspectives in medicine.

[6]  K. Attwood,et al.  High-dose interleukin-2 therapy for metastatic renal cell carcinoma: a contemporary experience. , 2014, Urology.

[7]  W. Weimar,et al.  Patient Survival After the Diagnosis of Cancer in Renal Transplant Recipients: A Nested Case-Control Study , 2010, Transplantation.

[8]  J. Neuberger,et al.  Comparison of the Incidence of Malignancy in Recipients of Different Types of Organ: A UK Registry Audit , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[9]  A. Webster,et al.  Validity of registry data: Agreement between cancer records in an end‐stage kidney disease registry (voluntary reporting) and a cancer register (statutory reporting) , 2010, Nephrology.

[10]  R. Alloway,et al.  De Novo Cancers Arising in Organ Transplant Recipients are Associated With Adverse Outcomes Compared With the General Population , 2009, Transplantation.

[11]  J. Holley Screening, diagnosis, and treatment of cancer in long-term dialysis patients. , 2007, Clinical journal of the American Society of Nephrology : CJASN.

[12]  J. Kaldor,et al.  Cancer incidence before and after kidney transplantation. , 2006, JAMA.

[13]  E. Bini,et al.  Predictive value of a positive fecal occult blood test increases as the severity of CKD worsens. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[14]  Patrick C. Walsh,et al.  American Cancer Society Guidelines for the Early Detection of Cancer , 2002, CA: a cancer journal for clinicians.

[15]  J. Holley Preventive Medical Screening Is Not Appropriate for Many Chronic Dialysis Patients , 2000, Seminars in dialysis.

[16]  K. Abbott,et al.  Life expectancy benefits of cancer screening in the end-stage renal disease population. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[17]  Cancer report. , 1970, British medical journal.

[18]  Robert A Smith,et al.  American Cancer Society Guidelines for the Early Detection of Cancer, 2006 , 2006, CA: a cancer journal for clinicians.